Guided chemotherapy for HER2-negative early breast cancer using drug screening

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of in vitro drug sensitivity screening to guide neoadjuvant chemotherapy for patients with HER2-negative early breast cancer. By utilizing a novel patient-derived tumor-like cell cluster technology, the study aims to identify which chemotherapy drugs are most effective for individual patients before treatment begins. A total of 46 participants will undergo this screening to tailor their chemotherapy regimen, potentially improving treatment outcomes and reducing unnecessary side effects. The study builds on preliminary findings that suggest a strong correlation between in vitro drug sensitivity and clinical outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* invasive breast cancer
* HER2 negative
* T2 or node positive
* Eastern Cooperative Oncology Group(ECOG) 0-1

Exclusion Criteria:

* stage IV
* inflammatory breast cancer
* Severe chronic disease

Where it's running

• Peking University People's Hospital
  Beijing, China Recruiting

Study contacts

• Principal investigator: Shu Wang, doctor — Peking University People's Hospital
• Study coordinator: Chaobin Wang, doctor
• Email: hzwcb1990@163.com
• Phone: +86-10-8832-4010

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Interferon-α Maintenance for Favorable-Risk AML

  This study tests pegylated interferon alfa-2b as maintenance therapy to see if it helps keep favorable-risk AML in remission after initial treatment.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07925554

• HLH after stem cell transplant: can routine blood tests flag risk in the next week?

  This study tests whether changes in common blood tests and clinical data can predict HLH within seven days after a first allogeneic stem cell transplant.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07905066

• MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC

  This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07894458

• ctDNA testing in newly diagnosed DLBCL or HGBL to predict treatment outcomes

  This study checks if measuring circulating tumor DNA in blood after first-line therapy can predict whether the disease will stay away or come back in people with DLBCL or HGBL.

  Recruiting at 2 sites Peking University People's Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07878351

• LECS with sentinel node navigation for early gastric cancer

  This study tests whether combining LECS with sentinel node navigation can treat early gastric cancer while preserving stomach function in eligible patients.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07857668

• Pilonidal sinus care with VAAPS and loose seton drainage after VAAPS

  This study tests whether adding a loose glove-edge seton drainage to VAAPS can allow patients to manage wound care at home without daily flushing.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07855107

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.